VR-CHOP regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of velcade (bortezomib), rituximab, cyclophosphamide,...") |
No edit summary |
||
| Line 6: | Line 6: | ||
{{PAGENAME}} refers to a regimen consisting of [[Bortezomib|velcade (bortezomib)]], [[rituximab]], [[cyclophosphamide]], [[Doxorubicin|hydroxydaunorubicin (doxorubicin)]], [[Vincristine|oncovin (Vincristine)]], [[prednisone]] used to treat previously untreated [[diffuse large B-cell lymphoma]] and [[mantle cell lymphoma]].<ref name="pmid21189393">{{cite journal| author=Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al.| title=Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 6 | pages= 690-7 | pmid=21189393 | doi=10.1200/JCO.2010.31.1142 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21189393 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[Bortezomib|velcade (bortezomib)]], [[rituximab]], [[cyclophosphamide]], [[Doxorubicin|hydroxydaunorubicin (doxorubicin)]], [[Vincristine|oncovin (Vincristine)]], [[prednisone]] used to treat previously untreated [[diffuse large B-cell lymphoma]] and [[mantle cell lymphoma]].<ref name="pmid21189393">{{cite journal| author=Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al.| title=Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 6 | pages= 690-7 | pmid=21189393 | doi=10.1200/JCO.2010.31.1142 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21189393 }} </ref> | ||
. | . | ||
==Regimen== | ==Regimen== | ||
{{chemo|V|Velcade (Bortezomib)}} | {{chemo|V|Velcade (Bortezomib)}} | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|H|Hydroxydaunorubicin (Doxorubicin)}} | {{chemo|H|Hydroxydaunorubicin (Doxorubicin)}} | ||
| Line 19: | Line 20: | ||
==Indications== | ==Indications== | ||
*[[Diffuse large B-cell lymphoma]] and [[Mantle cell lymphoma]].<ref name="pmid21189393">{{cite journal| author=Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al.| title=Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 6 | pages= 690-7 | pmid=21189393 | doi=10.1200/JCO.2010.31.1142 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21189393 }} </ref> | *[[Diffuse large B-cell lymphoma]] and [[Mantle cell lymphoma]].<ref name="pmid21189393">{{cite journal| author=Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al.| title=Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. | journal=J Clin Oncol | year= 2011 | volume= 29 | issue= 6 | pages= 690-7 | pmid=21189393 | doi=10.1200/JCO.2010.31.1142 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21189393 }} </ref> | ||
Revision as of 13:22, 30 March 2015
|
WikiDoc Resources for VR-CHOP regimen |
|
Articles |
|---|
|
Most recent articles on VR-CHOP regimen Most cited articles on VR-CHOP regimen |
|
Media |
|
Powerpoint slides on VR-CHOP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on VR-CHOP regimen at Clinical Trials.gov Trial results on VR-CHOP regimen Clinical Trials on VR-CHOP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on VR-CHOP regimen NICE Guidance on VR-CHOP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on VR-CHOP regimen Discussion groups on VR-CHOP regimen Patient Handouts on VR-CHOP regimen Directions to Hospitals Treating VR-CHOP regimen Risk calculators and risk factors for VR-CHOP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for VR-CHOP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VR-CHOP regimen refers to a regimen consisting of velcade (bortezomib), rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (Vincristine), prednisone used to treat previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.[1] .
Regimen
VVelcade (Bortezomib)
RRituximab
CCyclophosphamide
HHydroxydaunorubicin (Doxorubicin)
OOncovin (Vincristine)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM; et al. (2011). "Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma". J Clin Oncol. 29 (6): 690–7. doi:10.1200/JCO.2010.31.1142. PMID 21189393.